SPARK Europe Webinar Series | Wed, 11 Jan. 2023 | 4-5 pm (CET)
Dr. Ariel Kamsler “A view from the Bridge – Drug development from the perspective of a Venture Capital fund bridging the gap between Academic research and Industry”
What is the road a therapeutic travels from the lab to the clinic? What does a VC fund contribute to the process? What are some ways in which an academic lab can better prepare a project for industry attention and funding?
Dr. Ariel Kamsler, Associate and Head of Search and Evaluation at Israel Biotech Fund has years of experience in drug development management and evaluation.
Israel Biotech Fund is a VC fund focused on drug development companies based in Israel, the fund invests directly in companies in all stages of development and is active in company formation using pharmaceutical assets licensed from Pharma and from Academia.
Registration:
Online via Zoom – Please register here!
Registration for the webinar is required in advance, please register no later than 10 January 23.
This webinar is organized by SPARK Tel Aviv.
Contact:
Katharina Clausnitzer
katharina.clausnitzer@bih-charite.de
We very much look forward to welcoming you to our virtual events!
The webinars are open for all SPARKees, SPARK mentors, and students and staff of SPARK associated organizations.
SPARK Europe is the joint network of SPARK sites all over Europe including Israel: SPARK-BIH, SPARK Finland, SPARK FLI, SPARK Norway, SPARK Poland and SPARK Tel Aviv. European SPARK programs are members of SPARK Global network. The purpose of SPARK programs is to provide the education and mentorship necessary to advance research discoveries from the bench to the bedside, hence to increase the maturity of academic and clinical discoveries towards practical solutions that address unmet needs in the life science and health tech space. The program follows the same principles that have been the cornerstones of SPARK at Stanford since it was established by Professor Daria Mochly-Rosen and Kevin Grimes in 2006 for advancing new biomedical research discoveries into promising new treatments for patients.
